Kymera Therapeutics, Inc. (KYMR)
116.02
-2.61
(-2.20%)
USD |
NASDAQ |
Sep 03, 15:44
Kymera Therapeutics Research and Development Expense (TTM) : 367.34M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 367.34M |
| March 31, 2026 | 326.19M |
| December 31, 2025 | 308.26M |
| September 30, 2025 | 296.30M |
| June 30, 2025 | 282.76M |
| March 31, 2025 | 263.76M |
| December 31, 2024 | 232.88M |
| September 30, 2024 | 215.14M |
| June 30, 2024 | 203.94M |
| March 31, 2024 | 191.51M |
| December 31, 2023 | 185.52M |
| September 30, 2023 | 175.73M |
| June 30, 2023 | 171.59M |
| Date | Value |
|---|---|
| March 31, 2023 | 167.31M |
| December 31, 2022 | 161.23M |
| September 30, 2022 | 155.76M |
| June 30, 2022 | 150.28M |
| March 31, 2022 | 144.36M |
| December 31, 2021 | 134.59M |
| September 30, 2021 | 117.65M |
| June 30, 2021 | 95.32M |
| March 31, 2021 | 74.47M |
| December 31, 2020 | 60.72M |
| September 30, 2020 | 51.91M |
| June 30, 2020 | 47.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |
| Sarepta Therapeutics, Inc. | 783.60M |
| Anixa Biosciences, Inc. | 4.557M |